Merck (MRK) announced that the European Commission (EC) has approved two new indications for Keytruda, Merck’s anti-PD-1 therapy, in gynecologic cancers. The first approval is for Keytruda, in combination with carboplatin and paclitaxel, for the first-line treatment of primary advanced or recurrent endometrial carcinoma in adults who are candidates for systemic therapy. The second approval is for Keytruda, in combination with chemoradiotherapy, for the treatment of FIGO 2014 Stage III-IVA locally advanced cervical cancer in adults who have not received prior definitive therapy. With these decisions, Keytruda is now approved for 30 indications in the EU, including five in gynecologic cancers – three in endometrial cancer and two in cervical cancer.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- PMV provides update on Phase 2, Phase 1b portions of PYNNACLE trial
- Merck acquires Modifi Biosciences for $30M upfront
- Gilead, Merck announce from Phase 2 islatravir/lenacapavir combo study
- Merck reports ‘positive’ results from Phase 2b/3 trial of clesrovimab
- Uber downgraded, Zoom Video upgraded: Wall Street’s top analyst calls